



## Press Release

### **RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month**

TEL-AVIV, Israel and RALEIGH, N.C., October 16, 2019 [RedHill Biopharma Ltd.](#) (Nasdaq: [RDHL](#)) (Tel-Aviv Stock Exchange: [RDHL](#)) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced its support of a number of prevention and awareness initiatives for Stomach Cancer Awareness Month, including its sponsorship of the No Stomach For Cancer’s (NSFC) Spotlight on Stomach Cancer Symposium. The symposium will take place on Saturday, October 26, 2019, from 8 a.m. - 2 p.m. MST at the University of Arizona in Tucson, Arizona.

“We are proud to support No Stomach For Cancer in its efforts to raise awareness of stomach cancer, one of the major cancer types in terms of incidence and mortality worldwide,” **said Dr. June S. Almenoff, M.D., Ph.D., Chief Scientific Officer of RedHill Biopharma.** “*H. pylori* infection, which is classified by the World Health Organization as a Group 1 carcinogen, remains the leading risk factor for the development of gastric cancer, a devastating disease affecting more than one million individuals worldwide each year<sup>1</sup>. Eradication of *H. pylori* is associated with decreased risk of stomach cancer, and we recognize the importance of developing new treatments to overcome the growing antibiotic resistance to this prevalent bacterial infection.”

**Jon Florin, Executive Director of No Stomach For Cancer, said:** “We are grateful to have RedHill Biopharma as our title sponsor and to support our cause and educate others about *H. pylori*’s link to stomach cancer. November is Stomach Cancer Awareness Month, and this patient education symposium kicks off the awareness activities by gathering key opinion leaders in the stomach cancer space to share and discuss treatment options, and experiences around this disease.

---

<sup>1</sup> Bray, Freddie, et al. "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." *CA: a cancer journal for clinicians* 68.6 (2018): 394-424.

The ‘Spotlight on Stomach Cancer symposium’ provides a stage for experts, researchers, patients, and caregivers to learn more about the causes and risks of gastric cancer, in addition to current treatment options for patients. The event is free and open to the general public. To register for the event and receive more information please visit: <http://bit.ly/2lXunvO>.

### **About RedHill Biopharma Ltd.**

RedHill Biopharma Ltd. (Nasdaq: [RDHL](#)) (Tel-Aviv Stock Exchange: [RDHL](#)) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill commercializes and promotes several gastrointestinal products in the U.S.: **Donnatal**<sup>®</sup> - a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; **EnteraGam**<sup>®</sup> - a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools and **Mytesi**<sup>®</sup> - an anti-diarrheal drug indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. RedHill’s key clinical late-stage development programs include: (i) **RHB-105 (Talicia**<sup>®</sup>) for the treatment and eradication of *Helicobacter pylori* infection with a U.S. NDA submitted and accepted for priority review with a target PDUFA action date of November 2, 2019; (ii) **RHB-104**, with positive top-line results from a first Phase 3 study for Crohn’s disease; (iii) **RHB-204**, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) infections; (iv) **RHB-102 (Bekinda**<sup>®</sup>), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (v) **Yeliva**<sup>®</sup> (**ABC294640**), a first-in-class SK2 selective inhibitor, targeting multiple oncology, inflammatory and gastrointestinal indications, with an ongoing Phase 2a study for cholangiocarcinoma; (vi) **RHB-106**, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and (vii) **RHB-107**, a Phase 2-stage first-in-class, serine protease inhibitor, targeting cancer and inflammatory gastrointestinal diseases. More information about the Company is available at [www.redhillbio.com](http://www.redhillbio.com).

### **About No Stomach For Cancer**

No Stomach For Cancer (NSFC) is a 501(c)(3) non-profit organization whose mission is to support research and unite the caring power of people worldwide who are affected by stomach cancer. Headquartered in Wisconsin, and serving patients across the globe, the organization is a thought leader in stomach cancer awareness and education.

NSFC advances awareness and education about stomach cancer, including Hereditary Diffuse Gastric Cancer (HDGC), provides a support network for affected families, and supports research for screening, early detection, treatment, and prevention of stomach cancer. For more information, please visit [www.nostomachforcancer.org](http://www.nostomachforcancer.org). No Stomach For Cancer<sup>®</sup> and Stomach Cancer Awareness Month<sup>®</sup> are registered trademarks of No Stomach For Cancer, Inc.

*This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,”*

“will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks related to be commencement or timing of our clinical trials with RHB-104, for Crohn’s disease, RHB-204 for NTM infections RHB-102 (Bekinda<sup>®</sup>) and Yeliva<sup>®</sup> (ABC294640), risks related to the occurrence or timing of the RHB-105 (Taliccia<sup>®</sup>) PDUFA action date, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its therapeutic candidates; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates; (v) the Company’s ability to successfully commercialize and promote Donnatal<sup>®</sup>, EnteraGam<sup>®</sup> and Mytesi<sup>®</sup>; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company’s Expanded Access Program; (xiv) competition from other companies and technologies within the Company’s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on February 26, 2019, as amended on May 15, 2019. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

**Company contact:**

Adi Frish

Senior VP of Business Development & Licensing

RedHill Biopharma

+972-54-6543-112

[adi@redhillbio.com](mailto:adi@redhillbio.com)

**IR contact (U.S.):**

Timothy McCarthy, CFA, MBA

Managing Director, Relationship Manager

LifeSci Advisors, LLC

+1-212-915-2564

[tim@lifesciadvisors.com](mailto:tim@lifesciadvisors.com)